Why Is Teva Stock Trading Higher On Tuesday?
1. Teva initiated IND-enabling studies for BD9 targeting TH2-driven inflammatory diseases. 2. BD9 could improve outcomes in atopic dermatitis and asthma treatment. 3. Teva's recent stock increased by 6.01% to $17.98. 4. FDA approved Teva's ALVO Selarsdi as interchangeable with JNJ's Stelara. 5. Teva settled patent litigation with Axsome related to Auvelity.